Bupropion is the antidepressant least likely to cause sleepwalking
Based on the available evidence, bupropion is your best choice when sleepwalking risk is a concern, as it is not implicated in medication-induced sleepwalking literature and has a distinct mechanism of action that avoids the pathways associated with this adverse effect.
Why Bupropion?
The systematic review on medication-induced sleepwalking identified four primary drug classes that trigger sleepwalking: benzodiazepine receptor agonists, antidepressants and other serotonergic agents, antipsychotics, and β-blockers 1. The key mechanism appears to be drugs that enhance GABA activity, enhance serotonergic activity, or block noradrenergic β receptors 1.
Bupropion stands apart because it:
- Works primarily through dopamine and norepinephrine reuptake inhibition
- Has no significant serotonergic activity
- Does not enhance GABA activity
- Is not mentioned in sleepwalking case reports 1
Antidepressants That DO Cause Sleepwalking
The evidence specifically implicates serotonergic antidepressants in sleepwalking:
Mirtazapine: A documented case showed new-onset somnambulism when increased from 30 to 45 mg/day, with dramatic termination upon withdrawal 2. The mechanism relates to different affinities for 5-HT₂ and H₁ receptors at varying doses 2.
SSRIs and other serotonergic agents: Identified as triggers in the systematic review 1, and older literature notes they may induce or worsen parasomnia related to REM sleep 3.
Tricyclic antidepressants: Also implicated in sleepwalking, though historically used to treat some parasomnias 3.
Clinical Algorithm
When prescribing for depression with sleepwalking concerns:
- First choice: Bupropion (not associated with sleepwalking, activating profile)
- Avoid: Mirtazapine, SSRIs, and other serotonergic agents
- If sleepwalking develops on any antidepressant: Taper or discontinue immediately 2
- Patient education: Ensure safe sleep environment regardless of choice 1
Important Caveats
While bupropion avoids sleepwalking risk, it has an activating profile that can worsen insomnia in some patients 4. The ACP guidelines note that antidepressant selection should consider adverse effect profiles 5, and bupropion is associated with lower sexual dysfunction rates compared to SSRIs 5—an additional benefit.
The evidence base for sleepwalking with specific antidepressants relies primarily on case reports (except for zolpidem and sodium oxybate, which had strongest evidence) 1, but the mechanistic understanding clearly points away from bupropion as a culprit.